Correction to: Rheumatology and Therapy https://doi.org/10.1007/s40744-022-00498-x
In this article the legend for Fig. 5 was inadvertently with error, the legend for Fig. 5 should have appeared as shown below.
Fig. 5 LS mean CFB in mTSS among patients with any of the PPFs or four PPFs at A W24 or B W52. Each of the PPF subgroups [sero (+), hsCRP ≥ 6, DAS28(CRP) > 5.1, and erosion > 0] could include patients who also had other PPFs. *P < 0.05 versus PBO at W24; **P < 0.05 versus ADA at W52. Comparison to ADA at W24 is out of scope for statistical calculation. All treatment groups also received methotrexate. ADA adalimumab, CFB change from baseline, DAS28(CRP) disease activity score for rheumatoid arthritis in 28 joints with C-reactive protein, FIL100 filgotinib 100 mg, FIL200 filgotinib 200 mg, hsCRP high-sensitivity C-reactive protein, LS least squares, mTSS modified total Sharp score, PBO placebo, PPF poor prognostic factor, Sero (+) seropositivity for rheumatoid factor or anti-yclic citrullinated peptide, W week.
The original article is updated accordingly.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Combe, B.G., Tanaka, Y., Buch, M.H. et al. Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study. Rheumatol Ther 10, 71–72 (2023). https://doi.org/10.1007/s40744-022-00530-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40744-022-00530-0